Streetbeat News

OBIO

Orchestra BioMed Holdings, Inc.

Industry

Biotechnology

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

The article identifies four overbought health care stocks: Orchestra BioMed Holdings, Inc. (OBIO), Crinetics Pharmaceuticals, Inc. (CRNX), Takeda Pharmaceutical Company Limited (TAK), and NextGen Healthcare, Inc. (NXGN). These stocks are considered overvalued and present an opportunity to go short. The companies have recent developments such as FDA approvals, public offerings, and acquisitions.

Portfolio Pulse from Lisa Levin

September 21, 2023 | 11:51 am

The article lists the stocks that gained and lost the most in Wednesday's mid-day session. Among the gainers were MSP Recovery, Digital Transformation Opportunities Corp., Bluejay Diagnostics, Fresh Tracks Therapeutics, and AgriFORCE Growing Systems. Among the losers were Seelos Therapeutics, ARS Pharmaceuticals, Connexa Sports Technologies, Molekule Group, and IceCure Medical.

Portfolio Pulse from Lisa Levin

September 20, 2023 | 6:10 pm

Orchestra BioMed has received FDA approval for an investigational device exemption to start its global BACKBEAT study. The study will evaluate BackBeat CNT for hypertension in pacemaker patients, which has led to a rise in the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 2:44 pm

Several US stocks recorded gains in Tuesday's trading session. Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) jumped 24.4% after the FDA granted an investigational device exemption for a study. Rackspace Technology, Inc. (NASDAQ:RXT) rose 20.2% following an upgrade from Raymond James. Eos Energy Enterprises, Inc. (NASDAQ:EOSE), Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), Conduent Incorporated (NASDAQ:CNDT), Stem, Inc. (NYSE:STEM), Liberty TripAdvisor Holdings, Inc. (NASDAQ:LTRPB), Aspen Aerogels, Inc. (NYSE:ASPN), Waldencast plc (NASDAQ:WALD), Methanex Corporation (NASDAQ:MEOH), Lumen Technologies, Inc. (NYSE:LUMN), The Children's Place, Inc. (NASDAQ:PLCE), Array Technologies, Inc. (NASDAQ:ARRY), Semtech Corporation (NASDAQ:SMTC), Honda Motor Co., Ltd. (NYSE:HMC), and Vital Farms, Inc. (NASDAQ:VITL) also saw significant gains.

Portfolio Pulse from Lisa Levin

September 19, 2023 | 2:43 pm

The FDA has granted an Investigational Device Exemption to Orchestra Biomed for its BACKBEAT CNT therapy for hypertensive patients who are indicated for a dual-chamber cardiac pacemaker. This will allow the initiation of the BACKBEAT study.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 11:38 am

During Friday's intraday session, several healthcare stocks experienced significant movements. MSP Recovery (LIFW), Know Labs (KNW), Orchestra BioMed Hldgs (OBIO), Akso Health Group (AHG), Iovance Biotherapeutics (IOVA), and Soleno Therapeutics (SLNO) saw gains, while Avalo Therapeutics (AVTX), PTC Therapeutics (PTCT), First Wave BioPharma (FWBI), Novo Integrated Sciences (NVOS), Ambrx Biopharma (AMAM), and SeaStar Medical Holding (ICU) experienced losses.

Portfolio Pulse from Benzinga Insights

September 15, 2023 | 5:31 pm

Several stocks experienced significant price movements in Wednesday's mid-day session. First Wave BioPharma shares jumped 89.5% after announcing a license agreement for capeserod from Sanofi. PFSweb gained 48.3% following GXO Logistics' acquisition announcement. Taseko Mines, Avalo Therapeutics, NeuBase Therapeutics, MYT Netherlands Parent, Soluna Holdings, Nikola Corporation, Trinseo, Alaunos Therapeutics, Orchestra BioMed Holdings, Eiger BioPharmaceuticals, Uniti Group, Lixiang Education Holding, TransCode Therapeutics, and Novo Integrated Sciences also saw gains. On the other hand, Sezzle, Clearmind Medicine, BIOLASE, OKYO Pharma, IBEX, Bionomics, MicroCloud Hologram, Harpoon Therapeutics, ZyVersa Therapeutics, Super League Enterprise, Axcella Health, BIMI International Medical, Impel Pharmaceuticals, PureCycle Technologies, Ivanhoe Electric, SIMPPLE, Iovance Biotherapeutics, Radiant Logistics, CS Disco, Ambipar Emergency Response, Genius Sports, and Vital Energy saw declines.

Portfolio Pulse from Lisa Levin

September 14, 2023 | 4:58 pm

The article lists the stocks that gained and lost the most in Monday's mid-day session. Among the gainers were China SXT Pharmaceuticals, Timber Pharmaceuticals, and MediaCo Holding, while the losers included AgileThought, Napco Security Technologies, and Super League Gaming. The article also mentions that Palo Alto Networks rose after reporting better-than-expected Q4 earnings and a strong billings outlook, and that Moderna rose after announcing that preliminary clinical trial data confirmed its updated COVID-19 vaccine showed a significant boost in neutralizing antibodies against certain variants.

Portfolio Pulse from Lisa Levin

August 21, 2023 | 6:36 pm

Several healthcare stocks experienced significant price movements during Monday's intraday session. Gainers included Timber Pharmaceuticals (TMBR), China SXT Pharmaceuticals (SXTC), Novo Integrated Sciences (NVOS), China Pharma Holding (CPHI), Fortress Biotech (FBIOP), and Orchestra BioMed Hldgs (OBIO). Losers included CNS Pharma (CNSP), Arcutis Biotherapeutics (ARQT), Modular Medical (MODD), Frequency Therapeutics (FREQ), Vivos Therapeutics (VVOS), and Aziyo Biologics (AZYO).

Portfolio Pulse from Benzinga Insights

August 21, 2023 | 5:31 pm

Chardan Capital analyst Keay Nakae has reiterated a 'Buy' rating on Orchestra BioMed Holdings (NASDAQ:OBIO) and maintained a price target of $20.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 11:00 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.